Bal Pharma credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
160160150140131
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
154154140120123
1.94×1.94×1.94×2.02×2.06×
1.87×1.87×1.81×1.73×1.94×
5.00×5.00×5.09×4.43×5.21×
4.56×4.83×4.73×3.79×4.91×
1.24×1.24×1.17×1.41×1.31×
66.0%66.0%66.0%66.8%67.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BALPHARMA₹84.61

Bal Pharma Limited

· Pharma & Health
₹ CrorePeersALPAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹135 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt131.0139.6150.4159.5159.5
Net Debt123.4119.6139.9154.0154.0
Total Debt/Equity2.062.021.941.941.94
Net Debt/Equity1.941.731.811.871.87
Total Debt/EBITDA5.214.435.095.005.00
Net Debt/EBITDA4.913.794.734.834.56
Interest Coverage (EBIT/Interest)1.311.411.171.241.24
Total Debt/Total Capital %67.2866.8566.0265.9865.98
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.